Scientific article
English

Synthesis of a selective HDAC6 inhibitor active in neuroblasts

Published in

Bioorganic & medicinal chemistry letters, vol. 26, no. 20, p. 4955-4959

Publication date

2016

Abstract

In recent years, the role of HDAC6 in neurodegeneration has been partially elucidated, which led some authors to propose HDAC6 inhibitors as a therapeutic strategy to treat neurodegenerative diseases. In an effort to develop a selective HDAC6 inhibitor which can cross the blood brain barrier (BBB), a modified hydroxamate derivative (compound 3) was designed and synthetized. This compound was predicted to have potential for BBB penetration based on in silico and in vitro evaluation of passive permeability. When tested for its HDAC inhibitory activity, the IC50 value of compound 3 towards HDAC6 was in the nM range in both enzymatic and cell-based assays. Compound 3 showed a cell-based selectivity profile close to that of tubastatin A in SH-SY5Y human neuroblastoma cells, and a good BBB permeability profile.

Citation (ISO format)

ZWICK, Vincent et al. Synthesis of a selective HDAC6 inhibitor active in neuroblasts. In: Bioorganic & medicinal chemistry letters, 2016, vol. 26, n° 20, p. 4955–4959. doi: 10.1016/j.bmcl.2016.09.011

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0960-894X
410views
0downloads

Technical informations

Creation

13/06/2017 23:00:00

First validation

13/06/2017 23:00:00

Update

15/03/2023 01:47:28

Status update

15/03/2023 01:47:28

Last indexation

31/10/2024 07:12:43
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated